학술논문

Recommendations of the Advisory Committee on Immunization Practices for Use of Cholera Vaccine
Document Type
article
Source
MMWR Morbidity and Mortality Weekly Report. 66(18)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Biodefense
Emerging Infectious Diseases
Vaccine Related
Rare Diseases
Immunization
Prevention
Foodborne Illness
Biotechnology
Infectious Diseases
Digestive Diseases
Infection
Good Health and Well Being
Adolescent
Adult
Advisory Committees
Centers for Disease Control and Prevention
U.S.
Cholera
Cholera Vaccines
Humans
Middle Aged
Travel
United States
Young Adult
General & Internal Medicine
Language
Abstract
Cholera, caused by infection with toxigenic Vibrio cholerae bacteria of serogroup O1 (>99% of global cases) or O139, is characterized by watery diarrhea that can be severe and rapidly fatal without prompt rehydration. Cholera is endemic in approximately 60 countries and causes epidemics as well. Globally, cholera results in an estimated 2.9 million cases of disease and 95,000 deaths annually (1). Cholera is rare in the United States, and most U.S. cases occur among travelers to countries where cholera is endemic or epidemic. Forty-two U.S. cases were reported in 2011 after a cholera epidemic began in Haiti (2); however,